What is Trialjectory?
Trialjectory operates as a patient-first digital health enterprise, utilizing sophisticated artificial intelligence to bridge the gap between cancer patients and advanced clinical trials. The company empowers individuals to take ownership of their medical journey by providing actionable insights derived from its global patient community. By analyzing real-world evidence, Trialjectory enables patients to make informed, data-backed decisions regarding their treatment options. This market position is critical in an era where personalized medicine and patient advocacy are becoming central to the oncology landscape, effectively positioning the firm as a vital intermediary in the clinical research ecosystem.
How much funding has Trialjectory raised?
Trialjectory has raised a total of $22.7M across 2 funding rounds:
Angel/Seed
$2.7M
Series A
$20M
Angel/Seed (2019): $2.7M with participation from Contour Venture Partners
Series A (2022): $20M led by Rho Ventures, Insight Partners, JAL Ventures, Contour Venture Partners, and Tia Ventures
Key Investors in Trialjectory
Insight Partners
A global software-focused venture capital and private equity firm that provides deep operational support and a vast network to help portfolio companies scale effectively.
Rho Ventures
A long-standing venture capital firm that partners with entrepreneurs to build market-defining businesses through strategic guidance and extensive industry experience.
Contour Venture Partners
A New York-based seed-stage firm specializing in enterprise SaaS and B2B software, known for acting as a hands-on business partner to its portfolio companies.
What's next for Trialjectory?
With the infusion of capital from its latest financing round, Trialjectory is well-positioned to scale its operations and enhance its AI-driven platform capabilities. The company is expected to focus on expanding its global patient community and deepening its data analytics infrastructure to provide even more granular insights for clinical trial matching. As the firm transitions from its earlier growth phases into a more mature enterprise-level operation, the strategic focus will likely shift toward broader integration with healthcare providers and pharmaceutical partners, aiming to set new industry standards for patient-centric clinical research accessibility.
See full Trialjectory company page
